Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01763268|
Recruitment Status : Unknown
Verified January 2013 by Warunee Punpanich Vandepitte, Queen Sirikit National Institute of Child Health.
Recruitment status was: Recruiting
First Posted : January 8, 2013
Last Update Posted : January 8, 2013
Open-label, single-arm trial, Primary Objectives included:
- To assess the immunogenicity of TrivivacTM administered in healthy infants aged between 9-14 months.
- To assess the safety (reactogenicity) of TrivivacTM administered in healthy infants aged between 9-14 months.
The study will be done on healthy infants, 9-14 months of age. After enrolment, the infants will be given one dose of primary vaccination MMR (TrivivacTM),SEVAPHARMA BiogenetechLtd. study vaccines will be administered subcutaneously into the anterolateral aspect of right thigh.outer aspect of the upper arm. Subjects will be followed at approximately 6 weeks after primary vaccination to evaluate response to primary immunization of this vaccine. Blood sample will be collected from subjects at visit 1 (prior to immunization) and visit 2 (6 weeksone month after completion of this first dose of immunization). The serum samples will be analysed for Anti-measles, Anti-mumps and Anti-rubella antibodies. Proportion of subjects achieving seroprotection and geometric mean titers of antibody against measles, mumps, rubella at 6 weeks after one dose vaccination of MMR vaccine at aged 9-14 months will be evaluated. Adverse reactions will be observed on each vaccination day (up to 30 minutes) and for 4 days (Day 0-3) after each dose. Adverse reactions will also be monitored for 30 days following each vaccination. Serious adverse events will be monitored for the entire study duration.
|Condition or disease||Intervention/treatment||Phase|
|Immunogenicity Reactogenicity||Biological: Trivivac vaccine||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||January 2015|
|Estimated Study Completion Date :||August 2015|
Children who receive Trivivac vaccine
Biological: Trivivac vaccine
Trivalent MMR vaccine
- Immunogenicity as measured by the proportion of subjects achieving seroprotection against measles, mumps and rubella [ Time Frame: 6 weeks after vaccination ]
Immunogenicity of Trivivac vaccine is determined by proportion of subjects achieving seroprotection against measles, mumps and rubella at 6 weeks (42 days) after application of first dose of vaccine MMR. The amount of specific antibodies against measles, mumps and rubella will be evaluated in sera collected approximately 42+ 7 days following primary vaccination with the Trivivac vaccine.
Seroconversion and GMT against measles, mumps, and rubella will be defined by Enzyme immunoassay for the qualitative detection and quantitative determination of specific IgG antibodies against measles, mumps and rubella virus in human serum (Enzygnost® Anti-Measles Virus/IgG, Anti-Mumps Virus/IgG and Anti-Rubella Virus/IgG; SIEMENS).
- Reactogenicity as measured by the prevalence of local and systemic adverese reaction [ Time Frame: Day0 to day3 after vaccination ]Occurrence, intensity and relationship to vaccination of early expected and unexpected local and systemic adverse drug reactions reported during the 4-day (Day 0-3) follow-up period after vaccination.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763268
|Contact: Warunee P Vandepitte, MD, PhDfirstname.lastname@example.org|
|Queen Sirikit National Institute of Child Health||Recruiting|
|Bangkok, Thailand, 10400|
|Contact: Warunee Punpanich Vandepitte, MD, PhD 66855158299 email@example.com|
|Principal Investigator: Warunee P Vandepitte, MD, PhD|